Adelaide biotechnology company Bresagen's chief scientist, Dr Allan
Robins, has announced development of an equine hormone with potential to
earn South Australia millions of export dollars. The hormone has been proven to decrease athletic horses' breakdown rates and to enable faster recovery rates from injuries. The world market for the product has been conservatively estimated at $A150 million per annum. The hormone is planned to provide the three year old company's first revenue stream, and a float is likely, to secure the company's future growth.